529 related articles for article (PubMed ID: 10213505)
1. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K
Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505
[TBL] [Abstract][Full Text] [Related]
2. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
Koppan M; Nagy A; Schally AV; Arencibia JM; Plonowski A; Halmos G
Cancer Res; 1998 Sep; 58(18):4132-7. PubMed ID: 9751625
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
Plonowski A; Schally AV; Nagy A; Kiaris H; Hebert F; Halmos G
Cancer Res; 2000 Jun; 60(11):2996-3001. PubMed ID: 10850448
[TBL] [Abstract][Full Text] [Related]
4. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
Plonowski A; Schally AV; Nagy A; Sun B; Halmos G
Int J Oncol; 2002 Feb; 20(2):397-402. PubMed ID: 11788908
[TBL] [Abstract][Full Text] [Related]
5. Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
Kiaris H; Schally AV; Nagy A; Sun B; Szepeshazi K; Halmos G
Clin Cancer Res; 2000 Feb; 6(2):709-17. PubMed ID: 10690557
[TBL] [Abstract][Full Text] [Related]
6. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
[TBL] [Abstract][Full Text] [Related]
7. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
Szepeshazi K; Schally AV; Halmos G; Sun B; Hebert F; Csernus B; Nagy A
Clin Cancer Res; 2001 Sep; 7(9):2854-61. PubMed ID: 11555603
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
9. Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
Szereday Z; Schally AV; Szepeshazi K; Bajo AM; Hebert F; Halmos G; Nagy A
Int J Oncol; 2003 May; 22(5):1141-6. PubMed ID: 12684683
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Pinski J; Reile H; Halmos G; Groot K; Schally AV
Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
[TBL] [Abstract][Full Text] [Related]
11. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
Sato N; Gleave ME; Bruchovsky N; Rennie PS; Beraldi E; Sullivan LD
Cancer Res; 1997 Apr; 57(8):1584-9. PubMed ID: 9108464
[TBL] [Abstract][Full Text] [Related]
12. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL
Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines.
Glinsky GV; Price JE; Glinsky VV; Mossine VV; Kiriakova G; Metcalf JB
Cancer Res; 1996 Dec; 56(23):5319-24. PubMed ID: 8968076
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
[TBL] [Abstract][Full Text] [Related]
17. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
[TBL] [Abstract][Full Text] [Related]
18. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
Jackson JK; Gleave ME; Yago V; Beraldi E; Hunter WL; Burt HM
Cancer Res; 2000 Aug; 60(15):4146-51. PubMed ID: 10945622
[TBL] [Abstract][Full Text] [Related]
19. In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215.
Plonowski A; Nagy A; Schally AV; Sun B; Groot K; Halmos G
Int J Cancer; 2000 Nov; 88(4):652-7. PubMed ID: 11058885
[TBL] [Abstract][Full Text] [Related]
20. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
Engel JB; Keller G; Schally AV; Halmos G; Hammann B; Nagy A
Clin Cancer Res; 2005 Mar; 11(6):2408-15. PubMed ID: 15788692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
